Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques
npj Parkinsons Dis.. 2025-04-13; 11(1):
DOI: 10.1038/s41531-025-00938-9
Lire sur PubMed
1. NPJ Parkinsons Dis. 2025 Apr 13;11(1):75. doi: 10.1038/s41531-025-00938-9.
Additive effect of distant Lewy bodies and tau seeds injections on nigral
degeneration in macaques.
Darricau M(1), Kulifaj V(1)(2), Arotcarena ML(1), Li Q(3), Katsinelos T(4),
McEwan WA(4), Xilouri M(5), Dehay B(1), Bezard E(1)(6), Planche V(7)(8).
Author information:
(1)Université de Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France.
(2)University Clermont-Auvergne, CHU de Clermont-Ferrand, Clermont-Ferrand,
France.
(3)Motac Beijing services Ltd, Beijing, China.
(4)Department of Clinical Neurosciences, UK Dementia Research Institute,
University of Cambridge, Cambridge, UK.
(5)Center of Clinical Research, Experimental Surgery and Translational Research,
Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
(6)Motac Neuroscience Ltd, Bordeaux, France.
(7)Université de Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France.
.
(8)CHU de Bordeaux, Centre Mémoire Ressources Recherches, Service de Neurologie
des Maladies Neurodégénératives, Pôle de Neurosciences Cliniques, Bordeaux,
France. .
The influence of Lewy body (LB) and tau co-pathologies is increasingly
acknowledged as putatively affecting neurodegeneration and clinical phenotypes.
Here, we injected rhesus macaques with LB fractions or/and tau seeds derived
from patients brains into distinct brain areas connected to the mesencephalon.
Compared to control macaques, we observed increased mesencephalic staining of
pathological α-synuclein and tau, as well as nigrostriatal dopaminergic neuronal
loss, with a cumulative effect of co-pathology.
© 2025. The Author(s).
DOI: 10.1038/s41531-025-00938-9
PMCID: PMC11993647
PMID: 40221462
Conflict of interest statement: Competing interests: E.B. is a director and
shareholder of Motac Neuroscience Ltd. During the past 3 years, V.P. was a local
unpaid investigator or sub-investigator for clinical trials granted by Novo
Nordisk, Biogen, Janssen, and Alector. V.P. served as a consultant for Motac
Neuroscience Ltd, outside the submitted work. Other authors declare no competing
interests.